Almirall’s 17th Skin Academy Highlights Scientific Advances in Inflammatory Skin Diseases and Skin Cancer, Patient-Reported Outcomes, and Holistic Care in Medical Dermatology

Key Takeaways

• 800 experts convened to discuss dermatology breakthroughs
• Facial/neck atopic dermatitis identified as high unmet‑need area
• IL‑13 and IL‑23p19 therapies for severe cases
• WHO‑5 metric used to assess patient wellbeing
• Early actinic keratosis treatment aims to prevent cancer

Summary

Almirall hosted its 17th Skin Academy in Barcelona and Prague, drawing 800 dermatology professionals to discuss the latest science in medical dermatology. The program spotlighted new insights into atopic dermatitis—especially facial and neck involvement—and psoriasis, emphasizing patient‑reported outcomes and holistic care. Experts highlighted emerging IL‑13 and IL‑23p19 biologics, psycho‑dermatology tools such as the WHO‑5 wellbeing index, and early actinic keratosis treatment to curb skin cancer risk. Almirall reported 2025 revenue of €1.1 billion (approximately $1.2 billion) and reaffirmed its commitment to innovation.

Pulse Analysis

The 17th Skin Academy underscored Almirall’s role as a catalyst for collaboration in medical dermatology. By gathering clinicians, researchers, and industry leaders, the event created a platform where cutting‑edge data on inflammatory skin diseases could be exchanged, fostering faster translation of science into practice. This collaborative model not only enhances professional networks but also signals to investors that Almirall is deeply embedded in the innovation ecosystem that drives therapeutic advancement.

Scientific sessions tackled the most pressing gaps in atopic dermatitis and psoriasis care. Researchers presented data on IL‑13 inhibition and IL‑23p19 targeting, reinforcing the shift toward precision biologics for moderate‑to‑severe disease. A dedicated focus on facial and neck involvement highlighted the psychosocial burden of visible lesions, prompting discussions on new assessment tools and the integration of psycho‑dermatology metrics like WHO‑5. Parallel talks on actinic keratosis emphasized early intervention to prevent progression to squamous cell carcinoma, aligning with broader skin‑cancer prevention strategies.

From a business perspective, Almirall’s reported €1.1 billion revenue—about $1.2 billion—demonstrates the commercial potential of its dermatology portfolio. The emphasis on patient‑reported outcomes and holistic care positions the company to capture value beyond drug sales, including digital health solutions and supportive services. As the dermatology market expands with biologics and personalized therapies, Almirall’s continued investment in scientific forums like Skin Academy is likely to reinforce its competitive edge and drive sustained growth.